Bal Pharma Ltd has announced that Mr. Shreepada ML has commenced his duties as the Company Secretary and Compliance Officer effective June 23, 2026. The appointment places Mr. Shreepada ML in charge of the company's regulatory compliance and secretarial functions, ensuring adherence to statutory requirements and corporate governance norms.

Appointment Details

The company confirmed the development through a regulatory filing. Mr. Shreepada ML assumes the critical role responsible for overseeing the company's compliance framework.

The move comes as part of the company's routine administrative updates.

Bal Pharma reported a net profit of ₹675.12 lakh for the financial year ended March 31, 2026, a decline of 13.4% compared to ₹779.95 lakh in the previous year. Revenue from operations for the year rose 2.7% to ₹31,079.70 lakh from ₹30,249.64 lakh in FY25. The board has recommended a dividend of ₹1.20 per equity share, subject to shareholder approval at the ensuing Annual General Meeting. The company published these audited standalone and consolidated financial results in the Financial Express (English) and Sanjayvani (Kannada) on May 29, 2026, complying with Regulation 47 of the SEBI (LODR) Regulations, 2015.

Board Meeting Decisions

The Board of Directors met on May 27, 2026, to approve the audited standalone and consolidated financial results. In addition to the financial results, the board approved the preferential issue of 10,00,000 warrants to promoters and decided to seek shareholder approval for this fund-raising exercise through a postal ballot. The board also approved the grant of 5,00,000 stock options to employees under the Bal Pharma Limited – Employee Stock Option Plan-2025. Mr. Shreepada ML was appointed as Company Secretary and Compliance Officer, replacing Mr. Abdul Basith who resigned effective May 11, 2026.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹370.02 lakh, a decrease from ₹560.69 lakh in the same period last year. Quarterly revenue stood at ₹8,391.76 lakh. Total comprehensive income for the year increased to ₹718.50 lakh from ₹775.63 lakh in the previous year.

Auditor and Compliance

Statutory auditors SSJNB & Co issued an audit report with an unmodified opinion on the standalone and consolidated financial results. The board appointed Murugesh & Co as Internal Auditors and G.N.V & Associates as Cost Auditors for FY 2025-26. The trading window for designated persons and employees, which was closed from April 1, 2026, will remain closed until 48 hours after the declaration of financial results.